Summary.
The possibility of a pharmacokinetic and/or pharmacodynamic interaction between epanolol and digoxin has been investigated in 10 healthy male subjects taking digoxin 0.375 mg daily for 14 days. During that period epanolol 200 mg daily or matching placebo was also given, each for 7 days, according to a double-blind, randomized cross-over plan.
The plasma digoxin concentration-time profiles after 7 days of concomitant placebo or epanolol were comparable. Trough and peak plasma digoxin levels were similar (placebo: 0.84 and 2.62 ng · ml−1; epanolol: 0.87 and 2.46 ng · ml−1). The renal clearances of digoxin and creatinine were lower during treatment with epanolol, but the differences were not significant (placebo 142.0 and 126.5 ml · min−1; epanolol 105.7 and 109.3 ml · min−1).
STI indexes were lower during treatment with digoxin plus epanolol, than after digoxin alone. The difference was significant for QS2I (513 versus 503 ms), PEPI (119 versus 112 ms) and PEP/LVET (0.286 versus 0.304).
The observations suggest that in healthy volunteers there is no pharmacokinetic interaction between epanolol and digoxin, and that epanolol does not interfere with the positive inotropic action of digoxin.
Similar content being viewed by others
References
Belpaire FM, Bogaert MG (1976) Radioimmunoassay of digitalis glycosides. Acta Clin Belg 31: 212–221
Bilski AJ, Hardfield SE, Wale JL (1988) The pharmacology of epanolol (ICI 141292) — a new β1-selective adrenoceptor partial agonist. J Cardiovasc Pharmacol 12: 227–232
Cockroft DW, Gault MK (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41
Cockshott ID (1989) The pharmacokinetics of ICI 141,292 in healthy young volunteers and comparative data in elderly patients with angina and subjects with renal or hepatic impairment. Drugs 38 [Suppl 2], 10–17
Crawford MH, Lewinter MM, O'Rourke RA, Karliner JS, Ross J (1975) Combined propranolol and digoxin therapy in angina pectoris. Ann Intern Med 83: 449–455
Hansen PB, Buch J, Rasmussen O, Waldorff S, Steiness E (1984) Influence of atenolol and nifedipine on digoxin-induced inotropism in humans. Br J Clin Pharmacol 18: 817–822
Joubert PH, Belz GG (1987) Are pre-ejection period changes specific for inotropic effects? Eur J Clin Pharmacol 33: 335–336
Koup JR, Greenblatt DJ, Jusko WJ, Smith TW, Koch-Weser J (1975) Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm 3: 181–192
Rodin SM, Johnson BF (1988) Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 15: 227–244
Rousson D, Galleyrand J, Silie M, Boissel JP (1987) Uncorrected pre-ejection period: a simple non-invasive measurement for pharmacodynamic screening of inotropic activity. Eur J Clin Pharmacol 31: 559–562
Warrington SJ, Weerasuriya K, Burgess, CD (1988) Correction of systolic time intervals for heart rate: A comparison of individual with population derived regression equations. Br J Clin Pharmacol 26: 155–165
Weissler A, Harris WS, Schoenfeld CD (1968) Systolic time intervals in heart failure in man. Circulation 37: 149–159
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lefebvre, R.A., Bogaert, M.G. & Duprez, D. Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin. Eur J Clin Pharmacol 38, 505–507 (1990). https://doi.org/10.1007/BF02336692
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02336692